Table 1.
Characteristics of the studied population. Characteristics of the cohort at the beginning of the study
| Patient no. | Sex | Age (y) | Underlying nephropathy | Comorbidities | Medication | Dry weight (kg) | Dialyser surface area(m2) | Dialysis Duration (h) | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ischemic cardio-myopathy | Diabetes mellitus | Beta-blockers | Calcium antagonists | Alpha-blockers | ACE-inhibitors or ARB | |||||||
| 1 | F | 64 | Nephroangiosclerosis | N | N | Y | Y | N | Y | 57.00 | 1.8 | 3.0 |
| 2 | F | 56 | Nephroangiosclerosis | N | N | Y | Y | N | Y | 64.00 | 1.8 | 3.5 |
| 3 | F | 88 | Nephroangiosclerosis | N | N | Y | N | Y | Y | 64.00 | 1.8 | 3.0 |
| 4 | M | 59 | Focal segmental glomerulosclerosis | N | Y | Y | N | N | Y | 80.0 | 2.2 | 3.5 |
| 5 | F | 75 | Diabetic nephropathy | N | Y | Y | Y | Y | Y | 48.50 | 1.8 | 3.5 |
| 6 | M | 74 | Nephroangiosclerosis | N | N | N | N | N | N | 71.00 | 1.8 | 4.0 |
| 7 | M | 68 | IgA nephropathy | Y | N | N | N | N | Y | 94.65 | 1.8 | 4.0 |
| 8 | F | 65 | Diabetic nephropathy | Y | Y | Y | Y | Y | Y | 47.00 | 1.8 | 3.5 |
| 9 | F | 66 | Nephroangiosclerosis | N | N | N | Y | Y | N | 49.00 | 1.8 | 3.5 |
| 10 | M | 77 | Interstitial Nephritis | N | N | N | Y | N | Y | 99.50 | 1.8 | 3.5 |
| 11 | M | 72 | Nephroangiosclerosis | Y | N | Y | N | N | Y | 92.00 | 1.8 | 3.0 |
| 12 | F | 48 | IgA nephropathy | N | Y | Y | N | N | N | 64.50 | 2.2 | 3.5 |
| 13 | M | 77 | Nephroangiosclerosis | Y | N | Y | Y | N | N | 89.40 | 1.8 | 3.0 |
| 14 | M | 81 | Nephroangiosclerosis | N | N | Y | Y | N | N | 79.65 | 1.8 | 3.5 |
| 15 | M | 59 | Diabetic nephropathy | Y | Y | Y | N | N | Y | 99.00 | 1.8 | 4.0 |
| 16 | M | 88 | Nephroangiosclerosi | N | N | Y | N | N | N | 65.15 | 1.8 | 4.0 |
| 18 | M | 64 | Nephroangiosclerosis | N | Y | Y | Y | Y | N | 97.00 | 1.8 | 3.5 |
| 17 | F | 74 | Diabetic nephropathy | N | Y | N | Y | N | N | 80.00 | 1.8 | 3.5 |
| 19 | M | 65 | Focal segmental glomerulosclerosis | N | N | Y | N | N | N | 86.00 | 2.2 | 4.0 |
| 20 | F | 75 | Diabetic nephropathy | Y | Y | Y | N | N | Y | 68.50 | 1.8 | 3.0 |
| 21 | M | 81 | Nephroangiosclerosis | Y | N | Y | N | N | Y | 69.20 | 1.8 | 4.0 |
| 22 | M | 72 | Diabetic nephropathy | Y | Y | N | N | N | Y | 88.00 | 1.8 | 4.0 |
| 23 | M | 88 | Nephroangiosclerosis | Y | Y | N | Y | N | Y | 83.50 | 1.8 | 3.0 |
| 24 | M | 71 | Nephroangiosclerosis | Y | Y | Y | N | N | Y | 74.50 | 2.2 | 4.5 |
| 25 | F | 70 | Nephroangiosclerosis | N | N | Y | Y | N | Y | 48.20 | 1.8 | 3.0 |
M, male; F, female; Y, yes; N, no; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor antagonists